Ayham Alkhachroum1, Caroline A Der-Nigoghossian1, Elizabeth Mathews1, Nina Massad1, Riva Letchinger1, Kevin Doyle1, Wei-Ting Chiu1, Julie Kromm1, Clio Rubinos1, Angela Velazquez1, David Roh1, Sachin Agarwal1, Soojin Park1, E Sander Connolly1, Jan Claassen2. 1. From the Departments of Neurology (A.A., C.A.D.-N., E.M., N.M., R.L., K.D., W.-T.C., C.R., A.V., D.R., S.A., S.P., J.C.) and Neurosurgery (E.S.C.), Columbia University, New York, NY; and Departments of Critical Care Medicine and Clinical Neurosciences (J.K.), University of Calgary, Canada. 2. From the Departments of Neurology (A.A., C.A.D.-N., E.M., N.M., R.L., K.D., W.-T.C., C.R., A.V., D.R., S.A., S.P., J.C.) and Neurosurgery (E.S.C.), Columbia University, New York, NY; and Departments of Critical Care Medicine and Clinical Neurosciences (J.K.), University of Calgary, Canada. jc1439@columbia.edu.
Abstract
OBJECTIVE: To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively. We also studied the effect of high doses of ketamine on brain physiology as reflected by invasive multimodality monitoring (MMM). METHODS: We studied a consecutive series of 68 patients with SRSE who were admitted between 2009 and 2018, treated with ketamine, and monitored with scalp EEG. Eleven of these patients underwent MMM at the time of ketamine administration. We compared patients who had seizure cessation after ketamine initiation to those who did not. RESULTS: Mean age was 53 ± 18 years and 46% of patients were female. Seizure burden decreased by at least 50% within 24 hours of starting ketamine in 55 (81%) patients, with complete cessation in 43 (63%). Average dose of ketamine infusion was 2.2 ± 1.8 mg/kg/h, with median duration of 2 (1-4) days. Average dose of midazolam was 1.0 ± 0.8 mg/kg/h at the time of ketamine initiation and was started at a median of 0.4 (0.1-1.0) days before ketamine. Using a generalized linear mixed effect model, ketamine was associated with stable mean arterial pressure (odds ratio 1.39, 95% confidence interval 1.38-1.40) and with decreased vasopressor requirements over time. We found no effect on intracranial pressure, cerebral blood flow, or cerebral perfusion pressure. CONCLUSION: Ketamine treatment was associated with a decrease in seizure burden in patients with SRSE. Our data support the notion that high-dose ketamine infusions are associated with decreased vasopressor requirements without increased intracranial pressure. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ketamine decreases seizures in patients with SRSE.
OBJECTIVE: To test ketamine infusion efficacy in the treatment of super-refractory status epilepticus (SRSE), we studied patients with SRSE who were treated with ketamine retrospectively. We also studied the effect of high doses of ketamine on brain physiology as reflected by invasive multimodality monitoring (MMM). METHODS: We studied a consecutive series of 68 patients with SRSE who were admitted between 2009 and 2018, treated with ketamine, and monitored with scalp EEG. Eleven of these patients underwent MMM at the time of ketamine administration. We compared patients who had seizure cessation after ketamine initiation to those who did not. RESULTS: Mean age was 53 ± 18 years and 46% of patients were female. Seizure burden decreased by at least 50% within 24 hours of starting ketamine in 55 (81%) patients, with complete cessation in 43 (63%). Average dose of ketamine infusion was 2.2 ± 1.8 mg/kg/h, with median duration of 2 (1-4) days. Average dose of midazolam was 1.0 ± 0.8 mg/kg/h at the time of ketamine initiation and was started at a median of 0.4 (0.1-1.0) days before ketamine. Using a generalized linear mixed effect model, ketamine was associated with stable mean arterial pressure (odds ratio 1.39, 95% confidence interval 1.38-1.40) and with decreased vasopressor requirements over time. We found no effect on intracranial pressure, cerebral blood flow, or cerebral perfusion pressure. CONCLUSION:Ketamine treatment was associated with a decrease in seizure burden in patients with SRSE. Our data support the notion that high-dose ketamine infusions are associated with decreased vasopressor requirements without increased intracranial pressure. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ketamine decreases seizures in patients with SRSE.
Authors: Tracy Glauser; Shlomo Shinnar; David Gloss; Brian Alldredge; Ravindra Arya; Jacquelyn Bainbridge; Mary Bare; Thomas Bleck; W Edwin Dodson; Lisa Garrity; Andy Jagoda; Daniel Lowenstein; John Pellock; James Riviello; Edward Sloan; David M Treiman Journal: Epilepsy Curr Date: 2016 Jan-Feb Impact factor: 7.500
Authors: Jan Claassen; Angela Velazquez; Emma Meyers; Jens Witsch; M Cristina Falo; Soojin Park; Sachin Agarwal; J Michael Schmidt; Nicholas D Schiff; Jacobo D Sitt; Lionel Naccache; E Sander Connolly; Hans-Peter Frey Journal: Ann Neurol Date: 2016-08-16 Impact factor: 10.422
Authors: Eroboghene E Ubogu; Stephen M Sagar; Alan J Lerner; Brian N Maddux; José I Suarez; Mary Ann Werz Journal: Epilepsy Behav Date: 2003-02 Impact factor: 2.937
Authors: Eugen Trinka; Hannah Cock; Dale Hesdorffer; Andrea O Rossetti; Ingrid E Scheffer; Shlomo Shinnar; Simon Shorvon; Daniel H Lowenstein Journal: Epilepsia Date: 2015-09-04 Impact factor: 5.864
Authors: Nicolas Gaspard; Brandon Foreman; Lilith M Judd; James N Brenton; Barnett R Nathan; Blathnaid M McCoy; Ali Al-Otaibi; Ronan Kilbride; Ivan Sánchez Fernández; Lucy Mendoza; Sophie Samuel; Asma Zakaria; Giridhar P Kalamangalam; Benjamin Legros; Jerzy P Szaflarski; Tobias Loddenkemper; Cecil D Hahn; Howard P Goodkin; Jan Claassen; Lawrence J Hirsch; Suzette M Laroche Journal: Epilepsia Date: 2013-06-12 Impact factor: 5.864
Authors: Thais Dias Midega; Renato Carneiro de Freitas Chaves; Carolina Ashihara; Roger Monteiro Alencar; Verônica Neves Fialho Queiroz; Giovana Roberta Zelezoglo; Luiz Carlos da Silva Vilanova; Guilherme Benfatti Olivato; Ricardo Luiz Cordioli; Bruno de Arruda Bravim; Thiago Domingos Corrêa Journal: Rev Bras Ter Intensiva Date: 2022 Apr-Jun
Authors: Henning R Stetefeld; Alexander Schaal; Franziska Scheibe; Julia Nichtweiß; Felix Lehmann; Marcus Müller; Stefan T Gerner; Hagen B Huttner; Sebastian Luger; Hannah Fuhrer; Julian Bösel; Silvia Schönenberger; Konstantinos Dimitriadis; Bernhard Neumann; Kornelius Fuchs; Gereon R Fink; Michael P Malter Journal: Neurocrit Care Date: 2021-07-20 Impact factor: 3.210